Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06085742 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

Study acronym: BRE-08
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 165 wordsv4 See this version in full on ClinicalTrials.gov ↗
  2. Start date changed from estimate of Oct 2023 to Nov 22, 2023v3
  3. Primary endpoint revised Secondary endpoints revised (10) · Study title shortened, about 9 wordsv2 Show 2 more changesShow less
    • Secondary endpoints revised (10)
    • Study title shortened, about 9 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.
Trial Details
NCT Number NCT06085742
Lead Sponsor University of Illinois at Chicago
Conditions Breast Cancer
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov